GLP-1 receptor agonists are approved for the treatment of type 2 diabetes, and more recently for obesity treatment. The glucagon-like-peptide-1 (GLP-1) is a glucose dependent hormone produced by intestinal cells,...GLP-1 receptor agonists are approved for the treatment of type 2 diabetes, and more recently for obesity treatment. The glucagon-like-peptide-1 (GLP-1) is a glucose dependent hormone produced by intestinal cells, which is involved in insulin secretion and glucagon suppression. This hormone controls glucose plasma levels and reduces food intake. Additional effects were reported in slowing gastric emptying and in inducing satiety. In clinical practice, theGLP-1 receptor agonists are associated with significant reductions in glycosylated hemoglobin (HbA1c) and weight loss, despite showing a low risk of hypoglycemia. Beneficial effects have also been observed on blood pressure and lipid profile. The most common side effects associated with GLP-1 receptor agonists are gastro-intestinal motility disorders, such as nausea, vomiting and diarrhea, which are not associated with long-term health risks. Therefore, GLP-1 receptor agonists represent a relevant medication for type 2 diabetes, whose benefits may go far beyond glycemic control.展开更多
Aim: To assess the safety and efficacy of basal-supported prandial GLP-1 receptor agonist therapy (BPT)* in type 2 diabetes mellitus (T2DM). Methods: Patients with T2DM, who had previously received insulin injection t...Aim: To assess the safety and efficacy of basal-supported prandial GLP-1 receptor agonist therapy (BPT)* in type 2 diabetes mellitus (T2DM). Methods: Patients with T2DM, who had previously received insulin injection therapy and who had had their treatment switched to BPT (liraglutide), were retrospectively recruited. The efficacy of BPT was assessed by determining changes in HbA1c, body weight and total daily insulin dose from baseline to 4 months after BPT initiation. Safety was assessed by comparing the frequency of hypoglycemic episodes at baseline and after 4 months. The Wilcoxon test was used to analyze changes in parameters throughout the study period. Results: Twenty-nine patients, previously treated with basal-supported oral therapy (BOT), basal-bolus insulin, or pre-mixed insulin, were recruited. When analyzed together, there was no change in HbA1c throughout the study period, but body weight decreased (baseline 68.8 ± 13.2 kg vs. month 4 67.3 ± 13.1 kg;p < 0.001). Total daily insulin dose decreased after 4 months (baseline 24.4 ± 15.5 U/day vs. month 4 14.7 ± 9.2 U/day;p < 0.001), and there was no change in the frequency of hypoglycemic episodes. Analysis was conducted within sub-groups based on previous treatment modality. In the BOT group, HbA1c decreased from baseline after 2 months and body weight did not change throughout the study period. In both the basal-bolus insulin group and the pre-mixed insulin group, HbA1c remained steady throughout and there was a decrease in body weight. No change in the frequency of hypoglycemia was observed in any of the sub-groups. Conclusion: BPT in T2DM was associated with weight loss without changes in glycemic control over 4 months, suggesting that it may be an effective and safe therapy.展开更多
目的对比胰高血糖素样肽-1(GLP-1)受体激动剂和二肽基肽酶-4(DPP-4)抑制剂分别联合二甲双胍治疗2型糖尿病(T2DM)的疗效及对其血清抗氧因子、炎症因子的影响。方法将2020年5月至2022年5月中国中医科学院广安门医院南区收治的120例T2DM患...目的对比胰高血糖素样肽-1(GLP-1)受体激动剂和二肽基肽酶-4(DPP-4)抑制剂分别联合二甲双胍治疗2型糖尿病(T2DM)的疗效及对其血清抗氧因子、炎症因子的影响。方法将2020年5月至2022年5月中国中医科学院广安门医院南区收治的120例T2DM患者纳入本次前瞻性研究,采用随机数字表法分成GLP-1联合组(n=40)、DPP-4联合组(n=40)和对照组(n=40)。GLP-1联合组患者治疗方案为二甲双胍治疗+利拉鲁肽,DPP-4联合组患者治疗方案为二甲双胍+沙格列汀,对照组患者仅口服二甲双胍治疗。治疗为期6个月。比较3组患者治疗前后的血糖相关指标[空腹血糖、餐后2 h血糖(2 h PPG)、糖化血红蛋白(HbA1c)]及胰岛素抵抗指数(HOMA-IR)、氧化应激指标[超氧化物歧化酶(SOD)和6-酮-前列环素F1α(6-Keto-PGF1α)]和炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和超敏C反应蛋白(hs-CRP)]表达情况。结果GLP-1联合组治疗后的空腹血糖、2 hPPG、HbA1c和HOMA-IR分别为(5.05±0.69)mmol/L、(7.42±0.98)mmol/L、(6.11±0.70)%和(3.20±0.45),DPP-4联合组分别为(5.58±0.61)mmol/L、(8.09±1.04)mmol/L、(6.65±0.76)%和(3.78±0.50),对照组分别为(6.50±0.75)mmol/L、(10.14±1.22)mmol/L、(7.80±0.81)%和(4.61±0.59),GLP-1联合组与DPP-4联合组治疗后的上述血糖相关指标及HOMA-IR均较对照组显著下降,且GLP-1联合组显著低于DPP-4联合组,差异均有统计学意义(P<0.05)。GLP-1联合组治疗后的SOD和6-Keto-PGF1α分别为(95.09±9.97)U/mL、(76.19±6.80)ng/L,DPP-4联合组分别为(85.17±10.18)U/mL、(67.32±6.39)ng/L,对照组分别为(76.89±9.06)U/mL、(60.46±6.02)ng/L,GLP-1联合组与DPP-4联合组治疗后的血清SOD、6-Keto-PGF1α均较对照组显著上升,且GLP-1联合组血清SOD、6-Keto-PGF1α均较DPP-4联合组显著上升,差异均有统计学意义(P<0.05)。GLP-1联合组TNF-α、IL-6和hs-CRP分别为(7.05±1.16)ng/L、(5.01±1.35)pg/mL、(4.04±0.51)mg/L,DPP-4联合组为(7.93±1.29)ng/L、(5.97±1.40)pg/mL、(4.99±0.59)mg/L,对照组为(10.34±1.58)ng/L、(7.58±1.49)pg/mL、(5.94±0.64)mg/L,GLP-1联合组与DPP-4联合组治疗后的上述血清炎症因子均较对照组显著下降,且GLP-1联合组显著低于DPP-4联合组,差异均有统计学意义(P<0.05)。结论GLP-1受体激动剂联合二甲双胍治疗T2DM的降糖效果优于DPP-4受体抑制剂联合二甲双胍,在改善胰岛素抵抗和氧化应激,降低炎症反应方面同样优于DPP-4受体抑制剂联合二甲双胍治疗。展开更多
目的系统评价GLP-1受体激动剂(GLP-1RAs)对2型糖尿病患者骨折风险的影响。方法系统检索Pub Med、Medline、Embase、Cochrane图书馆、Web of science、CNKI及万方数据库。根据纳入排除标准筛选使用GLP-1RAs治疗2型糖尿病的随机对照试验(R...目的系统评价GLP-1受体激动剂(GLP-1RAs)对2型糖尿病患者骨折风险的影响。方法系统检索Pub Med、Medline、Embase、Cochrane图书馆、Web of science、CNKI及万方数据库。根据纳入排除标准筛选使用GLP-1RAs治疗2型糖尿病的随机对照试验(RCT)。利用Rev Man 5.0及Stata 12.0软件进行分析。结果最终纳入符合标准的RCT36篇,Meta分析结果显示:利拉鲁肽治疗2型糖尿病患者骨折风险低于对照组,差异有统计学意义[OR=0.47,95%CI(0.24,0.91),P=0.024],而与对照组相比,GLP-1 RAs[OR=0.94,95%CI(0.64,1.37),P=0.735]、艾塞那肽[OR=1.81,95%CI(0.83,3.95),P=0.139]、度拉鲁肽[OR=1.21,95%CI(0.57,2.58),P=0.616]、利西那肽[OR=1.27,95%CI(0.50,3.24),P=0.617]及阿必鲁肽[OR=0.70,95%CI(0.25,2.20),P=0.515],在骨折风险方面差异均无统计学意义。与对照组相比,GLP-1 RAs治疗对2型糖尿病患者骨折骨密度[OR=0.16,95%CI(-0.10,0.42),P=0.223]及血清钙[SMD=0.17,95%CI(-0.20,0.55),P=0.358]水平差异均无统计学意义。结论应用利拉鲁肽治疗2型糖尿病可降低患者骨折发生风险,而艾塞那肽等其他GLP-1 RAs及GLP-1 RAs总体骨折风险程度与对照组相似,且GLP-1 RAs对2型糖尿病患者骨密度及血清钙作用与对照组程度相似。展开更多
目的:探讨人胰升糖素样肽1(glucagonlike peptide-1,GLP-1)受体激动剂利拉鲁肽对2型糖尿病患者结肠镜检查肠道准备质量的影响。方法:前瞻性纳入2014年11月至2017年10月首次行结肠镜检查且接受口服降糖药物联用利拉鲁肽或胰岛素治疗的2...目的:探讨人胰升糖素样肽1(glucagonlike peptide-1,GLP-1)受体激动剂利拉鲁肽对2型糖尿病患者结肠镜检查肠道准备质量的影响。方法:前瞻性纳入2014年11月至2017年10月首次行结肠镜检查且接受口服降糖药物联用利拉鲁肽或胰岛素治疗的2型糖尿病患者195例,以聚乙二醇电解质散4L分次口服方案进行肠道准备,采用渥太华肠道准备评分量表(Ottawa Bowel Preparat ion Scale,OBPS)和肠道准备满意度(OBPS评分≤6分)比例评估肠道准备质量。结果:口服降糖药物联用利拉鲁肽(利拉鲁肽组)87例,联用胰岛素(胰岛素组)108例,2组基线资料具有可比性(P>0.05)。利拉鲁肽组和胰岛素组OBPS评分相似(5.86±1.74 vs 5.54±1.81,t=1.270,P=0.206),肠道准备满意率相似(81.6%vs 82.4%,χ~2=0.021,P=0.885)。2组肠道准备期间均未见低血糖事件发生。结论:GLP-1受体激动剂利拉鲁肽对2型糖尿病患者结肠镜检查肠道准备质量的影响较小。展开更多
文摘GLP-1 receptor agonists are approved for the treatment of type 2 diabetes, and more recently for obesity treatment. The glucagon-like-peptide-1 (GLP-1) is a glucose dependent hormone produced by intestinal cells, which is involved in insulin secretion and glucagon suppression. This hormone controls glucose plasma levels and reduces food intake. Additional effects were reported in slowing gastric emptying and in inducing satiety. In clinical practice, theGLP-1 receptor agonists are associated with significant reductions in glycosylated hemoglobin (HbA1c) and weight loss, despite showing a low risk of hypoglycemia. Beneficial effects have also been observed on blood pressure and lipid profile. The most common side effects associated with GLP-1 receptor agonists are gastro-intestinal motility disorders, such as nausea, vomiting and diarrhea, which are not associated with long-term health risks. Therefore, GLP-1 receptor agonists represent a relevant medication for type 2 diabetes, whose benefits may go far beyond glycemic control.
文摘Aim: To assess the safety and efficacy of basal-supported prandial GLP-1 receptor agonist therapy (BPT)* in type 2 diabetes mellitus (T2DM). Methods: Patients with T2DM, who had previously received insulin injection therapy and who had had their treatment switched to BPT (liraglutide), were retrospectively recruited. The efficacy of BPT was assessed by determining changes in HbA1c, body weight and total daily insulin dose from baseline to 4 months after BPT initiation. Safety was assessed by comparing the frequency of hypoglycemic episodes at baseline and after 4 months. The Wilcoxon test was used to analyze changes in parameters throughout the study period. Results: Twenty-nine patients, previously treated with basal-supported oral therapy (BOT), basal-bolus insulin, or pre-mixed insulin, were recruited. When analyzed together, there was no change in HbA1c throughout the study period, but body weight decreased (baseline 68.8 ± 13.2 kg vs. month 4 67.3 ± 13.1 kg;p < 0.001). Total daily insulin dose decreased after 4 months (baseline 24.4 ± 15.5 U/day vs. month 4 14.7 ± 9.2 U/day;p < 0.001), and there was no change in the frequency of hypoglycemic episodes. Analysis was conducted within sub-groups based on previous treatment modality. In the BOT group, HbA1c decreased from baseline after 2 months and body weight did not change throughout the study period. In both the basal-bolus insulin group and the pre-mixed insulin group, HbA1c remained steady throughout and there was a decrease in body weight. No change in the frequency of hypoglycemia was observed in any of the sub-groups. Conclusion: BPT in T2DM was associated with weight loss without changes in glycemic control over 4 months, suggesting that it may be an effective and safe therapy.
文摘目的对比胰高血糖素样肽-1(GLP-1)受体激动剂和二肽基肽酶-4(DPP-4)抑制剂分别联合二甲双胍治疗2型糖尿病(T2DM)的疗效及对其血清抗氧因子、炎症因子的影响。方法将2020年5月至2022年5月中国中医科学院广安门医院南区收治的120例T2DM患者纳入本次前瞻性研究,采用随机数字表法分成GLP-1联合组(n=40)、DPP-4联合组(n=40)和对照组(n=40)。GLP-1联合组患者治疗方案为二甲双胍治疗+利拉鲁肽,DPP-4联合组患者治疗方案为二甲双胍+沙格列汀,对照组患者仅口服二甲双胍治疗。治疗为期6个月。比较3组患者治疗前后的血糖相关指标[空腹血糖、餐后2 h血糖(2 h PPG)、糖化血红蛋白(HbA1c)]及胰岛素抵抗指数(HOMA-IR)、氧化应激指标[超氧化物歧化酶(SOD)和6-酮-前列环素F1α(6-Keto-PGF1α)]和炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和超敏C反应蛋白(hs-CRP)]表达情况。结果GLP-1联合组治疗后的空腹血糖、2 hPPG、HbA1c和HOMA-IR分别为(5.05±0.69)mmol/L、(7.42±0.98)mmol/L、(6.11±0.70)%和(3.20±0.45),DPP-4联合组分别为(5.58±0.61)mmol/L、(8.09±1.04)mmol/L、(6.65±0.76)%和(3.78±0.50),对照组分别为(6.50±0.75)mmol/L、(10.14±1.22)mmol/L、(7.80±0.81)%和(4.61±0.59),GLP-1联合组与DPP-4联合组治疗后的上述血糖相关指标及HOMA-IR均较对照组显著下降,且GLP-1联合组显著低于DPP-4联合组,差异均有统计学意义(P<0.05)。GLP-1联合组治疗后的SOD和6-Keto-PGF1α分别为(95.09±9.97)U/mL、(76.19±6.80)ng/L,DPP-4联合组分别为(85.17±10.18)U/mL、(67.32±6.39)ng/L,对照组分别为(76.89±9.06)U/mL、(60.46±6.02)ng/L,GLP-1联合组与DPP-4联合组治疗后的血清SOD、6-Keto-PGF1α均较对照组显著上升,且GLP-1联合组血清SOD、6-Keto-PGF1α均较DPP-4联合组显著上升,差异均有统计学意义(P<0.05)。GLP-1联合组TNF-α、IL-6和hs-CRP分别为(7.05±1.16)ng/L、(5.01±1.35)pg/mL、(4.04±0.51)mg/L,DPP-4联合组为(7.93±1.29)ng/L、(5.97±1.40)pg/mL、(4.99±0.59)mg/L,对照组为(10.34±1.58)ng/L、(7.58±1.49)pg/mL、(5.94±0.64)mg/L,GLP-1联合组与DPP-4联合组治疗后的上述血清炎症因子均较对照组显著下降,且GLP-1联合组显著低于DPP-4联合组,差异均有统计学意义(P<0.05)。结论GLP-1受体激动剂联合二甲双胍治疗T2DM的降糖效果优于DPP-4受体抑制剂联合二甲双胍,在改善胰岛素抵抗和氧化应激,降低炎症反应方面同样优于DPP-4受体抑制剂联合二甲双胍治疗。
文摘目的:探讨人胰升糖素样肽1(glucagonlike peptide-1,GLP-1)受体激动剂利拉鲁肽对2型糖尿病患者结肠镜检查肠道准备质量的影响。方法:前瞻性纳入2014年11月至2017年10月首次行结肠镜检查且接受口服降糖药物联用利拉鲁肽或胰岛素治疗的2型糖尿病患者195例,以聚乙二醇电解质散4L分次口服方案进行肠道准备,采用渥太华肠道准备评分量表(Ottawa Bowel Preparat ion Scale,OBPS)和肠道准备满意度(OBPS评分≤6分)比例评估肠道准备质量。结果:口服降糖药物联用利拉鲁肽(利拉鲁肽组)87例,联用胰岛素(胰岛素组)108例,2组基线资料具有可比性(P>0.05)。利拉鲁肽组和胰岛素组OBPS评分相似(5.86±1.74 vs 5.54±1.81,t=1.270,P=0.206),肠道准备满意率相似(81.6%vs 82.4%,χ~2=0.021,P=0.885)。2组肠道准备期间均未见低血糖事件发生。结论:GLP-1受体激动剂利拉鲁肽对2型糖尿病患者结肠镜检查肠道准备质量的影响较小。
